Experiments suggest that SARS-CoV-2 infections after vaccination trigger antibody levels similar to those in people whose infections preceded their vaccination.
against the SARS-CoV-2 spike protein, one of the immune system’s main targets when it is fending off the virus. These individuals’ blood serum — which contains antibodies — blocks a diverse array of SARS-CoV-2 variants, and does so more effectively than serum from vaccinated people who were never infected and serum from people whose immunity comes from infection only.
Microbiologist Fikadu Tafesse at Oregon Health & Science University in Portland and his colleagues analysed serum from three groups of health-care workers: some who’d had breakthrough infections, others who’d been infected before they were vaccinated, and vaccinated people with no history of infection. In laboratory assays, the sera from both groups with previous infections had higher levels of antibodies against the spike protein than did serum from people protected only by vaccines.
, although the team has not yet looked at activity against Omicron. The researchers report their work in a 25 January study in
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Breakthrough COVID powers up immune response to variants — including OmicronExperiments suggest that SARS-CoV-2 infections after vaccination trigger antibody levels similar to those in people whose infections preceded their vaccination.
Consulte Mais informação »
As Omicron Declines, U.S. Rethinks Mask Guidance and Covid-19 MeasuresAs mask mandates loosen and cases fall, health experts say the U.S. must bolster its defenses and prepare for any future surges.
Consulte Mais informação »
S.Korea turns to self-treatment as Omicron fuels COVID surgeSouth Korea said on Thursday patients with mild coronavirus symptoms will have to treat themselves, aiming to free up medical resources for more serious cases, as new infections hit a fresh high because of the fast spreading Omicron variant.
Consulte Mais informação »
FDA authorizes new Covid antibody drug to fight omicron variantThe FDA has cleared a new antibody drug, that targets the omicron variant, for adults and adolescent patients with mild-to-moderate cases.
Consulte Mais informação »
GSK, Vir Say Their Covid Antibody Treatment Can Neutralize Fast-Spreading Omicron RelativeI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Consulte Mais informação »
After hopeful early signs, study of popular heartburn drug shows mixed results against Covid-19The trial, believed to be the first of its kind, was small, and the effect was far from dramatic.
Consulte Mais informação »